Immuneering Corporation - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
IMRX Nasdaq 2836 immuneering.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Immuneering Corporation

Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - Oct 2nd, 2026 7:00 am
Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer - Sep 28th, 2026 5:30 am
Immuneering to Present at the ESMO Congress 2026 - Sep 24th, 2026 5:30 am
Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival - Sep 10th, 2026 5:30 am
Immuneering to Participate in Upcoming Investor Conferences - Sep 3rd, 2026 2:05 pm
Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients - Aug 26th, 2026 3:16 pm
Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls - Aug 6th, 2026 7:48 am
Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates - Aug 5th, 2026 5:30 am
Publication in Cancer Research Details Atebimetinib’s Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition - Jul 21st, 2026 2:05 pm
Immuneering Corporation Announces Grants of Inducement Awards - Jul 17th, 2026 2:05 pm
Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know - Jul 15th, 2026 10:00 am
Immuneering Appoints Andrew Gengos as Chief Financial Officer - Jun 15th, 2026 5:30 am
IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up - Jun 12th, 2026 7:48 am
IMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff? - Jun 1st, 2026 1:58 pm
Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO - Jun 1st, 2026 5:30 am
Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates - May 15th, 2026 5:35 am
We're Hopeful That Immuneering (NASDAQ:IMRX) Will Use Its Cash Wisely - May 6th, 2026 8:53 am